tetano
Editor, Senior Moderator
Mod Rheumatol Case Rep
. 2023 Jan 5;rxac093.
doi: 10.1093/mrcr/rxac093. Online ahead of print.
Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09: 01 allele
Takuro Kawamura[SUP] 1 [/SUP], Daigo Nakazawa[SUP] 1 [/SUP], Saori Nishio[SUP] 1 [/SUP], Taiki Isozaki[SUP] 1 [/SUP], Maki Komatsumoto[SUP] 1 [/SUP], Tatsuya Atsumi[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents with severe pneumonia and fatal systemic complications. Currently, SARS-CoV-2 vaccines are effective in reducing the risk of new onset and getting worse of the disease. However, autoimmune diseases such as antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) have been reported to develop after COVID-19 vaccine administration. Case presentation: A 71-year-old woman presented with fever, malaise, urinary abnormalities and renal dysfunction after receiving the COVID-19 vaccine (Pfizer-BioNTech). We clinically diagnosed AAV with her manifestations and serological test (MPO-ANCA positive). Her clinical findings were improved after immunosuppressive therapy. We examined her genetic susceptibility to AAV and we found that her allele was HLA-DRB1*09:01, which is a risk allele of MPO-AAV. Mechanistically, SARS-CoV-2 vaccines would activate immunity, including neutrophils, and trigger AAV onset in this patient with a genetic risk to develop AAV. The pathophysiology of this case would share with that of autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in the absence of external adjuvants.
Keywords: ANCA associated vasculitis; ASIA; COVID-19; HLA-DRB1*09: 01 allele; SARS-CoV-2 vaccines.
. 2023 Jan 5;rxac093.
doi: 10.1093/mrcr/rxac093. Online ahead of print.
Development of ANCA-associated vasculitis followed by SARS-CoV-2 vaccination in a patient with HLA-DRB1*09: 01 allele
Takuro Kawamura[SUP] 1 [/SUP], Daigo Nakazawa[SUP] 1 [/SUP], Saori Nishio[SUP] 1 [/SUP], Taiki Isozaki[SUP] 1 [/SUP], Maki Komatsumoto[SUP] 1 [/SUP], Tatsuya Atsumi[SUP] 1 [/SUP]
Affiliations
- PMID: 36610742
- DOI: 10.1093/mrcr/rxac093
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), presents with severe pneumonia and fatal systemic complications. Currently, SARS-CoV-2 vaccines are effective in reducing the risk of new onset and getting worse of the disease. However, autoimmune diseases such as antineutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) have been reported to develop after COVID-19 vaccine administration. Case presentation: A 71-year-old woman presented with fever, malaise, urinary abnormalities and renal dysfunction after receiving the COVID-19 vaccine (Pfizer-BioNTech). We clinically diagnosed AAV with her manifestations and serological test (MPO-ANCA positive). Her clinical findings were improved after immunosuppressive therapy. We examined her genetic susceptibility to AAV and we found that her allele was HLA-DRB1*09:01, which is a risk allele of MPO-AAV. Mechanistically, SARS-CoV-2 vaccines would activate immunity, including neutrophils, and trigger AAV onset in this patient with a genetic risk to develop AAV. The pathophysiology of this case would share with that of autoimmune/inflammatory syndrome induced by adjuvants (ASIA) in the absence of external adjuvants.
Keywords: ANCA associated vasculitis; ASIA; COVID-19; HLA-DRB1*09: 01 allele; SARS-CoV-2 vaccines.